JP2024086827A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024086827A5 JP2024086827A5 JP2024062460A JP2024062460A JP2024086827A5 JP 2024086827 A5 JP2024086827 A5 JP 2024086827A5 JP 2024062460 A JP2024062460 A JP 2024062460A JP 2024062460 A JP2024062460 A JP 2024062460A JP 2024086827 A5 JP2024086827 A5 JP 2024086827A5
- Authority
- JP
- Japan
- Prior art keywords
- uapc
- cell
- composition
- cells
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633587P | 2018-02-21 | 2018-02-21 | |
| US62/633,587 | 2018-02-21 | ||
| JP2020544206A JP7591405B2 (ja) | 2018-02-21 | 2019-02-21 | ユニバーサル抗原提示細胞およびその使用 |
| PCT/US2019/018989 WO2019165097A1 (en) | 2018-02-21 | 2019-02-21 | Universal antigen presenting cells and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544206A Division JP7591405B2 (ja) | 2018-02-21 | 2019-02-21 | ユニバーサル抗原提示細胞およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024086827A JP2024086827A (ja) | 2024-06-28 |
| JP2024086827A5 true JP2024086827A5 (enExample) | 2025-03-18 |
Family
ID=67686940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544206A Active JP7591405B2 (ja) | 2018-02-21 | 2019-02-21 | ユニバーサル抗原提示細胞およびその使用 |
| JP2024062460A Pending JP2024086827A (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544206A Active JP7591405B2 (ja) | 2018-02-21 | 2019-02-21 | ユニバーサル抗原提示細胞およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200390815A1 (enExample) |
| EP (1) | EP3755347B1 (enExample) |
| JP (2) | JP7591405B2 (enExample) |
| KR (1) | KR20200123459A (enExample) |
| CN (1) | CN112292137A (enExample) |
| AU (1) | AU2019226021B2 (enExample) |
| BR (1) | BR112020016876A2 (enExample) |
| CA (1) | CA3091671A1 (enExample) |
| DK (1) | DK3755347T3 (enExample) |
| ES (1) | ES3035716T3 (enExample) |
| FI (1) | FI3755347T3 (enExample) |
| MX (1) | MX2020008801A (enExample) |
| MY (1) | MY210248A (enExample) |
| PL (1) | PL3755347T3 (enExample) |
| PT (1) | PT3755347T (enExample) |
| SG (1) | SG11202008008UA (enExample) |
| WO (1) | WO2019165097A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178701A1 (en) * | 2020-03-05 | 2021-09-10 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| WO2021042072A1 (en) * | 2019-09-01 | 2021-03-04 | Exuma Biotech Corp. | Methods and compositions for the modification and delivery of lymphocytes |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| CN113316455A (zh) * | 2018-11-29 | 2021-08-27 | 得克萨斯大学体系董事会 | 用于离体扩增自然杀伤细胞的方法及其用途 |
| KR20220004992A (ko) * | 2019-03-29 | 2022-01-12 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Car-nk 세포의 생산 방법 및 이의 용도 |
| EP4342913B1 (en) * | 2021-05-19 | 2025-12-17 | Shanghai Escugen Biotechnology Co., Ltd. | Chimeric antigen receptor molecule for specifically recognizing baff-r and application of chimeric antigen receptor molecule |
| CN113832190A (zh) * | 2021-09-24 | 2021-12-24 | 中海峡(福建)细胞生物科技有限公司 | 一种利用基因工程修饰的滋养细胞的制备方法及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
| US5939281A (en) | 1996-09-16 | 1999-08-17 | Case Western Reserve University | Detecting alloreactivity |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| WO2000006588A1 (en) | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| WO2005035570A2 (en) | 2003-10-10 | 2005-04-21 | Xencor, Inc. | Variants of cd40l protein |
| ES2653570T3 (es) * | 2004-05-27 | 2018-02-07 | The Trustees Of The University Of Pennsylvania | Células presentadoras de antígeno artificiales novedosas y usos de las mismas |
| CA2605631A1 (en) | 2005-04-20 | 2006-10-26 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms |
| US9121008B2 (en) * | 2005-08-31 | 2015-09-01 | University Of Utah Research Foundation | Development of natural killer cells and functional natural killer cell lines |
| WO2009039854A2 (en) * | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| CN102597223B (zh) * | 2009-09-11 | 2017-05-10 | 宝生物工程株式会社 | 生产天然杀伤细胞的方法 |
| WO2013163171A1 (en) | 2012-04-24 | 2013-10-31 | Kaufman Dan S | Method for developing natural killer cells from stem cells |
| WO2014005072A1 (en) * | 2012-06-28 | 2014-01-03 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for natural killer cells |
| WO2015132415A1 (en) * | 2014-03-07 | 2015-09-11 | Emercell Sas | Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease |
| WO2015154012A1 (en) * | 2014-04-03 | 2015-10-08 | Memorial Sloan-Kettering Cancer Center | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations |
| US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
| EP3223856B1 (en) | 2014-10-27 | 2025-09-24 | University of Central Florida Research Foundation, Inc. | Methods and compositions for natural killer cells |
| AU2015338958A1 (en) * | 2014-10-31 | 2017-05-11 | Baylor College Of Medicine | Survivin specific T-cell receptor targeting tumor but not T cells |
| WO2016197108A1 (en) * | 2015-06-05 | 2016-12-08 | Board Of Regents, The University Of Texas System | Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type |
| EP3138905A1 (en) * | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
| CN115537372A (zh) * | 2016-07-13 | 2022-12-30 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| SG11201810871WA (en) * | 2016-07-25 | 2019-01-30 | Us Health | Methods of producing modified natural killer cells and methods of use |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
| CN113316455A (zh) * | 2018-11-29 | 2021-08-27 | 得克萨斯大学体系董事会 | 用于离体扩增自然杀伤细胞的方法及其用途 |
-
2019
- 2019-02-21 DK DK19757670.5T patent/DK3755347T3/da active
- 2019-02-21 MY MYPI2020004259A patent/MY210248A/en unknown
- 2019-02-21 ES ES19757670T patent/ES3035716T3/es active Active
- 2019-02-21 AU AU2019226021A patent/AU2019226021B2/en active Active
- 2019-02-21 CA CA3091671A patent/CA3091671A1/en active Pending
- 2019-02-21 KR KR1020207027108A patent/KR20200123459A/ko not_active Ceased
- 2019-02-21 PL PL19757670.5T patent/PL3755347T3/pl unknown
- 2019-02-21 US US16/970,930 patent/US20200390815A1/en active Pending
- 2019-02-21 PT PT197576705T patent/PT3755347T/pt unknown
- 2019-02-21 SG SG11202008008UA patent/SG11202008008UA/en unknown
- 2019-02-21 FI FIEP19757670.5T patent/FI3755347T3/fi active
- 2019-02-21 BR BR112020016876-9A patent/BR112020016876A2/pt unknown
- 2019-02-21 CN CN201980021995.0A patent/CN112292137A/zh active Pending
- 2019-02-21 EP EP19757670.5A patent/EP3755347B1/en active Active
- 2019-02-21 MX MX2020008801A patent/MX2020008801A/es unknown
- 2019-02-21 WO PCT/US2019/018989 patent/WO2019165097A1/en not_active Ceased
- 2019-02-21 JP JP2020544206A patent/JP7591405B2/ja active Active
-
2024
- 2024-04-09 JP JP2024062460A patent/JP2024086827A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024086827A5 (enExample) | ||
| Knorr et al. | Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy | |
| Butler et al. | Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy | |
| TWI836160B (zh) | 製備用於ｔ細胞治療之ｔ細胞的方法 | |
| Stroncek et al. | New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer | |
| JP2024150721A (ja) | Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物 | |
| Alvarez-Fernández et al. | A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy | |
| JP2019523001A5 (enExample) | ||
| Yang et al. | Challenges and opportunities of allogeneic donor-derived CAR T cells | |
| Kagoya et al. | Transient stimulation expands superior antitumor T cells for adoptive therapy | |
| Berg et al. | Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells | |
| Zappasodi et al. | The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells | |
| JP2025031794A5 (enExample) | ||
| Delalat et al. | 3D printed lattices as an activation and expansion platform for T cell therapy | |
| CN1541113A (zh) | 利用激活的t细胞使抗原提呈细胞成熟 | |
| Xu et al. | Toward precision manufacturing of immunogene T-cell therapies | |
| Brauer et al. | T cell genesis: in vitro veritas est? | |
| FI3755347T3 (fi) | Universaaleja antigeeniä esitteleviä soluja ja niiden käyttöjä | |
| Perro et al. | Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer | |
| MX2023008162A (es) | Composiciones y metodos para la expansion de celulas t y linfocitos infiltrantes del tumor. | |
| Boucher et al. | Large scale ex vivo expansion of Γδ T cells using artificial antigen-presenting cells | |
| US20210087530A1 (en) | Compositions and methods for culturing and expanding cells | |
| Bagheri et al. | Current progress in cancer immunotherapy based on natural killer cells | |
| Yee | Adoptive therapy using antigen-specific T-cell clones | |
| JPWO2021021963A5 (enExample) |